Reuters logo
BRIEF-Kempharm and Genco Sciences announce technology licensing agreement to develop prodrug-based therapy for tourette’s syndrome with ADHD
2017年10月4日 / 中午11点33分 / 14 天前

BRIEF-Kempharm and Genco Sciences announce technology licensing agreement to develop prodrug-based therapy for tourette’s syndrome with ADHD

Oct 4 (Reuters) - Kempharm Inc:

* Kempharm and Genco Sciences announce technology licensing agreement to develop prodrug-based therapy for potential rare pediatric indications of tourette’s syndrome with ADHD

* Kempharm Inc says ‍Kempharm will be responsible for financing and managing all product development​

* Says ‍in exchange, co will retain full intellectual property and commercial ownership of any product developed as a result of the agreement​

* Says ‍Genco eligible to receive certain milestone and royalty-based or value share payments​

* Says ‍additional details about agreement were not disclosed​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below